Company intelligence / Profile preview

Orphinic Scientific

Warsaw, Mazowieckie, Polandorphinic.com ↗
Ownership
Private
Employees
~15
Development stage
Other
01

Overview

Company has an advanced clinical pipeline with multiple projects in Phase 1/2, with first exit projected in Q4 2024. The portfolio includes over 10 products across pharmaceutical and medtech segments.

Therapeutic areas
CardiovascularNeurologyMen's HealthRare Diseases
Modalities
Small moleculeGene therapyDevice
Industry
Biotech
02

Drug pipeline

3 assets

Bioxyma

Preclinical

2 more assets in the full pipeline.

Beyond the preview

Go deeper on Orphinic Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orphinic Scientific.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call